Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 26, 2019

View Archived Issues

Gene editing extends life span of progeria mice

Salt plays role in dermatitis risk

The ties that bind synapses

TBL1Y gene mutation tied to hereditary hearing loss

TC BioPharm collaborates with Trinity College Dublin on V delta 1 products for cancer

Grant to support IND submission and phase I trials of Hummingbird's HMBD-002

Imuran and Azanin approved in Japan to treat autoimmune hepatitis

Listeria shown to evade killing by hijacking host mitophagy

Lentiviral gene therapy with OTL-101 shows safety and efficacy in patients with ADA-SCID

Novel dual AAV-mediated gene therapy shows efficacy in DFNB9 mouse model

NT-I7 demonstrates tumor killing in vivo and enhances survival in mice

3B Pharmaceuticals collaborates with Boehringer Ingelheim on peptide-led drug discovery

Toll-like receptor 7/8/9 antagonists discovered at Bristol-Myers Squibb

Goldfinch Biopharma discloses TrpC5 antagonists

Servicios Cientificos Neuroinnovation patents tau protein ligands

Dyax discovers plasma kallikrein inhibitors

Detailed results from phase III trials of Dupixent in chronic rhinosinusitis with nasal polyps

Phase III POLO trial of Lynparza in pancreatic cancer meets primary endpoint of PFS

Phase III study shows subcutaneous daratumumab is noninferior to intravenous daratumumab

FDA approves Lonsurf for previously treated gastric or gastroesophageal junction adenocarcinoma

New phase I trial evaluates MK-8527 in ART-naive patients with HIV-1

Lilly synthesizes new phosphodiesterase PDE1 inhibitors

Modified mRNA encoding VEGF-A evaluated in patients with type 2 diabetes

Favorable interim phase I results for SRK-015 support progression to phase II for SMA

Debiopharm begins phase II study of afabicin for staphylococcal bone and joint infections

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...